[18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease
Status:
RECRUITING
Trial end date:
2029-09-01
Target enrollment:
Participant gender:
Summary
This clinical trial aims to evaluate whether \[F\]AlF-OC PET/MRI can characterize and quantify inflammation in carotid atherosclerotic plaques. The study will assess if tracer uptake in culprit and non-culprit carotid arteries, measured by standardized uptake values (SUV), is associated with future cerebrovascular events. Specifically, it will examine whether \[F\]AlF-OC uptake predicts the risk of recurrent ipsilateral TIA, amaurosis fugax, stroke, or other vascular complications.
Participants will undergo \[F\]AlF-OC PET/MRI and will be followed via telephone interviews at 90 days, 1 year, and 3 years after their initial stroke or TIA.